Compounds · Semaglutide · continued

Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold? posts 61–63

Compounds › Semaglutide randomised trial type 2 diabetes STEP programme effect size Solved

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.

OkaforTL3Regular5 Dec 2024#61

The STEP programme populations were selected: enrollment criteria required baseline body mass index over 30, no recent blood pressure crisis, no recent retinopathy, no renal disease at the time. Applying results from that population to someone well outside it is an extrapolation and should be called one.

14 likes 20mo

n.szaboTL2 Moderator5 Dec 2024#62

steady_state, post #49: post #48 is right about the mechanism and I think understates the practical bit. Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up. Go to post

Coming back to post #60, because the follow-up matters more than the original answer.

Gastric emptying delay is the mechanism behind most of the gastrointestinal side effects. Slowing the stomach empties it feeds less food into the intestines at a time, which is part of the satiety mechanism but is also why nausea is dose-dependent and titration-dependent.

29 likes in reply to #49 20mo

a.stephanopoulosTL3Regular6 Dec 2024 · edited#63

b.dumitru, post #8: The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Go to post

post #62 answers the question as asked. The question underneath it is different.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

0 likes in reply to #8 20mo

Promoted into the documentation commons. The content of this topic is maintained at Liraglutide — reference, with named maintainers and a review date. The promotion was discussed in doc review. Corrections are best raised against the document, which is the version that gets kept current.

Moved from Retatrutide by hana.sato. Category placement is not obvious from outside and getting it wrong is expected. This topic will get better answers here. The move is recorded in the public log citing R7.

Suggested topics

Topic	Participants	Replies	Views	Activity
Molecular mass of semaglutide and why the figure differs between sources — does this still hold? Compounds › Semaglutide effect size type 2 diabetes STEP programme SELECT trial Solved Closed Molecular mass of semaglutide and why the figure differs between sources — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SURPASS-2 (…	+94	102	14k	19mo
The C-cell question: rodent findings and their human context — what changed since Compounds › Semaglutide effect size SELECT trial randomised trial type 2 diabetes Closed The C-cell question: rodent findings and their human context — what changed since — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support…	+61	65	1.3k	22mo
Semaglutide in people without diabetes: what the evidence base looks like Compounds › Semaglutide semaglutide effect size STEP programme randomised trial Semaglutide in people without diabetes: what the evidence base looks like Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl J Med , 2016).…	+2	6	18k	17mo
What the published dose-response for semaglutide actually looks like above 2.4 mg Compounds › Semaglutide STEP programme type 2 diabetes effect size SELECT trial Solved What the published dose-response for semaglutide actually looks like above 2.4 mg — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 ( JAMA ,…		2	10k	3mo
Is there a ceiling dose beyond which semaglutide stops adding benefit? Compounds › Semaglutide effect size type 2 diabetes SELECT trial Is there a ceiling dose beyond which semaglutide stops adding benefit? I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in…		2	14k	2mo

Related topics — sharing the tags randomised trial, type 2 diabetes, STEP programme

Topic	Participants	Replies	Views	Activity
SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Compounds › Tirzepatide SURMOUNT programme randomised trial tirzepatide SURPASS programme Solved Closed Posting this under the heading it deserves: SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med…	+122	136	48k	9mo
Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small Compounds › Oral incretins PIONEER programme orforglipron randomised trial SOUL trial Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURPASS-4 ( Lancet , 2021)…		2	17k	6h
Gallbladder disease risk with rapid weight loss Clinical › Comorbidities obstructive sleep apnoea type 2 diabetes chronic kidney disease Solved Posting this under the heading it deserves: Gallbladder disease risk with rapid weight loss Everything below is what sits behind that. General question, not a request for advice about my own care — I know the…	+56	63	34k	18mo
Second pass at: Historical amylin analogues and what happened to them Compounds › Cagrilintide & amylin analogues amylin analogues effect size cagrilintide cagrisema Closed Second pass at: Historical amylin analogues and what happened to them — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim…	+15	19	22k	18mo
The arithmetic of an intermediate dose between two label steps Practice › Dosing & titration dose reduction semaglutide missed dose On the subject in the title: The arithmetic of an intermediate dose between two label steps Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am…		2	136	2mo